The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Keratoconjunctivitis sicca
5,6) The most frequent clinical features associated with Sjogren syndrome, namely, keratoconjunctivitis sicca
and xerostomia, are nonspecific and highly subjective.
A review of the Keratoconjunctivitis sicca
(Dry Eye) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
This report provides elemental information and data relating to the clinical trials on Keratoconjunctivitis sicca
Dry eye syndrome, also known as keratoconjunctivitis sicca
(KCS), is a multi-factorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation.
A Phase 1 clinical trial of R348 eye drops is underway in patients with chronic dry eye disease, otherwise known as keratoconjunctivitis sicca
The company is developing LX214 as a potential treatment for keratoconjunctivitis sicca
, commonly known as dry eye syndrome (DES), and other chronic inflammatory ocular surface diseases.
R348, Topical Ophthalmic JAK/SYK Inhibitor Chronic dry eye, or Keratoconjunctivitis Sicca
, is a relatively common inflammatory condition affecting the lacrimal glands of the eye.
05 percent), as the first and only therapeutic treatment for patients with the tear deficiency of keratoconjunctivitis sicca
(or dry eye disease), whose tear production is presumed to be suppressed due to ocular inflammation.
LX214 was also efficacious in a preliminary study in a dog model of keratoconjunctivitis sicca